DIRECT (DIabetes REsearCh on patient straTification) is a consortium looking at personalized medicine for type 2 diabetes. The aims of the consortium are to identify biomarkers that address current bottlenecks in diabetes drug development and to develop a stratified medicines approach to the treatment of type 2 diabetes with either existing or novel therapies.
The consortium consists of 25 European partners, with seven interrelated research work packages, covering phenotype generation and provision, data generation and analysis, validation and assay development and validation through prospective clinical trials.
Jane Kaye, Karen Melham and Harriet Teare are the HeLEX researchers working on this project, and will be responsible for identifying, addressing and resolving ethical, legal and regulatory issues that emerge as the scientific work programmes develop and to ensure the development of best practice. Part of this work will focus in particular on patient engagement.
The DIRECT project started in January 2012 and will run for 7 years. The project is supported by the Innovative Medicines Initiative (IMI), which is part of the EU Seventh Framework Programme (FP7).
The project partners are:
- Sanofi-Aventis Deutschland GmbH
- Eli Lilly and Company Ltd.
- University of Dundee
- University of Bath
- Consiglio Nazionale delle Ricerche
- Technical University of Denmark
- Eberhard Karls Universität Tübingen
- Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH
- Consorci Institut D`Investigacions Biomediques August Pi i Sunyer
- Imperial College London
- Kungliga Tekniska Högskolan
- University of Lille – CNRS
- Leiden University Medical Center
- University of Copenhagen
- University of Eastern Finland
- Lunds Universitet
- University of Newcastle upon Tyne
- University of Exeter
- University of Gèneve
- University of Oxford
- Universität Ulm
- VU University Medical Center Amsterdam
- Novo Nordisk A/S
- Lille University Hospital